Marine Polymer Technologies
Privately held medical device company developing and commercializing biomaterial-based products for wound healing and hemostasis. Technologies are based on poly-N-acetyl glucosamine (pGlcNAc) nanofibers derived from microalgae. The company conducts preclinical and clinical research, publishes peer-reviewed evidence, and markets topical hemostatic dressings and bio-active wound matrices for hospital, surgical and trauma settings.
Industries
Nr. of Employees
medium (51-250)
Marine Polymer Technologies
Danvers, Massachusetts, United States
Patents
Application of polymeric materials to screens to facilitate hemostasis and wound healing
US-10252040-B2
View Details
Application of polymeric materials to screens to facilitate hemostasis and wound healing
US-10252040-B2
View DetailsProducts
Topical vascular-access hemostasis system
A non-invasive topical dressing designed to control bleeding at vascular catheterization access sites and enable early ambulation, including use in anticoagulated patients.
Bio-active wound-healing matrix
A bio-active nanofiber matrix for management of acute and chronic wounds that promotes angiogenesis, granulation tissue formation and re-epithelialization.
Trauma hemostatic dressing for severe bleeding control
A rapid-deployment hemostatic bandage intended for temporary control of severe venous and arterial hemorrhage, including use in coagulopathic patients.
GlykoSL REF 400-13
GlykoSL is a conformable, soft and absorbent calcium alginate dressing attached to a foam backing, indicated for use in the local management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.
SyvekExcel Patch
A soft, white, sterile, lyophilized pad of a cellulosic polymer isolated from microalgae, attached to medical grade foam backing, intended for the local management and rapid control of bleeding wounds.
Syvek Patch
A soft, white, sterile non-woven pad of a cellulosic polymer isolated from microalgae designed to promote the rapid control of bleeding in patients on anticoagulation therapy.
Topical vascular-access hemostasis system
A non-invasive topical dressing designed to control bleeding at vascular catheterization access sites and enable early ambulation, including use in anticoagulated patients.
Bio-active wound-healing matrix
A bio-active nanofiber matrix for management of acute and chronic wounds that promotes angiogenesis, granulation tissue formation and re-epithelialization.
Trauma hemostatic dressing for severe bleeding control
A rapid-deployment hemostatic bandage intended for temporary control of severe venous and arterial hemorrhage, including use in coagulopathic patients.
GlykoSL REF 400-13
GlykoSL is a conformable, soft and absorbent calcium alginate dressing attached to a foam backing, indicated for use in the local management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.
SyvekExcel Patch
A soft, white, sterile, lyophilized pad of a cellulosic polymer isolated from microalgae, attached to medical grade foam backing, intended for the local management and rapid control of bleeding wounds.
Syvek Patch
A soft, white, sterile non-woven pad of a cellulosic polymer isolated from microalgae designed to promote the rapid control of bleeding in patients on anticoagulation therapy.
Services
Collaborative clinical studies and preclinical projects with academic centers and hospitals to evaluate biomaterial wound-healing and hemostatic products.
Collaborative clinical studies and preclinical projects with academic centers and hospitals to evaluate biomaterial wound-healing and hemostatic products.
Expertise Areas
- Wound-healing biomaterials
- Hemostasis device development
- Randomized clinical trials for wound and hemostasis products
- Preclinical hemorrhage and wound-model testing
Key Technologies
- Poly-N-acetyl glucosamine (pGlcNAc) nanofibers
- Bio-active wound matrix technology
- Topical hemostatic dressings and bandages
- Platelet activation and thrombin-generation assays
News & Updates
Centers for Medicare & Medicaid Services awarded pass-through status (APC 1449) facilitating reimbursement for the application of a wound matrix in hospital outpatient and ambulatory surgical center settings.
Federal Circuit en banc decision affirmed a prior judgment awarding damages and a permanent injunction concerning patents covering biocompatible p-GlcNAc polymers.
U.S. District Court entered a permanent injunction prohibiting a competitor from making or selling certain products found to infringe a patent related to p-GlcNAc polymers.
Randomized pilot study published showing increased complete healing of venous leg ulcers at 20 weeks with addition of the bio-active matrix versus standard care.
Health-economics review (funded by the company) found substantial variation in incremental cost to achieve healing with different advanced wound care matrices.
Regulatory clearance for a poly-N-acetyl glucosamine-based wound-management matrix for management of diabetic ulcers, venous ulcers, pressure ulcers, partial- and full-thickness wounds, second-degree burns and other wounds.
Centers for Medicare & Medicaid Services awarded pass-through status (APC 1449) facilitating reimbursement for the application of a wound matrix in hospital outpatient and ambulatory surgical center settings.
Federal Circuit en banc decision affirmed a prior judgment awarding damages and a permanent injunction concerning patents covering biocompatible p-GlcNAc polymers.
U.S. District Court entered a permanent injunction prohibiting a competitor from making or selling certain products found to infringe a patent related to p-GlcNAc polymers.
Randomized pilot study published showing increased complete healing of venous leg ulcers at 20 weeks with addition of the bio-active matrix versus standard care.
Health-economics review (funded by the company) found substantial variation in incremental cost to achieve healing with different advanced wound care matrices.
Regulatory clearance for a poly-N-acetyl glucosamine-based wound-management matrix for management of diabetic ulcers, venous ulcers, pressure ulcers, partial- and full-thickness wounds, second-degree burns and other wounds.